Everything below concerns circadian rhythm. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-15. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
In 2003, arsenic trioxide (under the trade name Trisenox) was re-introduced for the treatment of acute promyelocytic leukaemia, a cancer of the blood and bone marrow. Arsenic in drinking water, which causes lung and bladder cancer, has been associated with a reduction in breast cancer mortality rates. Metallic antimony is relatively non-toxic, but most antimony compounds are poisonous. Two antimony compounds, sodium stibogluconate and stibophen, are used as antiparasitical drugs. Elemental tellurium is not considered particularly toxic; two grams of sodium tellurate, if administered, can be lethal. People exposed to small amounts of airborne tellurium exude a foul and persistent garlic-like odour. Tellurium dioxide has been used to treat seborrhoeic dermatitis; other tellurium compounds were used as antimicrobial agents before the development of antibiotics. In the future, such compounds may need to be substituted for antibiotics that have become ineffective due to bacterial resistance. Of the elements less often recognised as metalloids, beryllium and lead are noted for their toxicity; lead arsenate has been extensively used as an insecticide. Sulfur is one of the oldest of the fungicides and pesticides. Phosphorus, sulfur, zinc, selenium, and iodine are essential nutrients, and aluminium, tin, and lead may be. Sulfur, gallium, selenium, iodine, and bismuth have medicinal applications. Sulfur is a constituent of sulfonamide drugs, still widely used for conditions such as acne and urinary tract infections.
=== Luteal phase === Immediately after the LH surge and subsequent ovulation, estradiol concentrations drop and the corpus luteum develops. Towards the end of luteal phase, GnSAF production in the small antral follicles increases steadily. FSH does not stimulate GnSAF production in the corpus luteum, so GnSAF bioactivity is low after ovulation, until the intercycle rise in FSH occurs.
=== Viable epidermis === Below the stratum corneum is the viable epidermis. The viable epidermis is usually 50–100 μm thick. It includes immunologically sensitive cells (e.g. Langerhans cells), and metabolically active cells (e.g. keratinocytes, melanocytes, merkel cells). Melanocytes are involved in melanoma pathogenesis. As a result, drugs treating melanoma need to be administered to the lower epidermis.
Sources: en.wikipedia.org
A documentary by Mike "Zappy" Zapolin, in which famous NBA athlete (and former Keeping Up With the Kardashians star) Lamar Odom seeks out ibogaine and other therapies to heal PTSD, anxiety, and addiction. In Waves and War (2024). A Netflix documentary in which Navy SEALS with PTSD seek therapy using ibogaine through a program run by Stanford University.
== Production == The donkey is considered a seasonal polyestrous animal. However, the latitudinal location of the farm can greatly impact the reproduction cycle. The female is normally pregnant for about 12 months. Donkey milk production differs greatly from that of conventional dairy species, especially in terms of milk supply, which is much more limited. The equid mammary gland has a low capacity (max 2.5 L) and a part of the milk production should be left to the foal. Milking may be carried out two or three hours after separation from the foal. Donkeys should be milked three times a day from 20 to 90 days after foaling. A female produces between 0.5 and 1.3 litres of milk a day for about 6–7 months. The variability of donkey milk production is due to many factors, such as individual milkability, nutrition, genetics and management of reproduction, in addition to milking management. Generally, a donkey farm for milk production is small, and has rarely more than ten heads or so. The largest donkey farm in Europe is found in northern Italy. The Montebaducco donkey farm in Quattro Castella, a comune in Emilia Romagna, Italy, has 800 donkey heads.
== In popular culture == In 2016, Singaporean director Boo Junfeng directed and released a film titled Apprentice, starring Firdaus Rahman and Wan Hanafi Su. The film, which narrates the fictional story of newly appointed prison officer and executioner Aiman Yusof, touched on the subject of the death penalty in Singapore and an executioner's perspective of the practice, as well as the experiences and ostracisation of the families when their loved ones were tried and executed. The director also revealed that he had gathered information through interviews of the retired executioners, imams and priests who counselled the death row inmates, and also the families of the executed prisoners while producing the film. The film, which was released in several international film festivals, was met with positive public responses and it attracted both nominations and awards for the director and production team. In Singapore, there were local crime shows like In Cold Blood, Crimewatch, and True Files which re-enact the real-life crimes in Singapore. Among these cases, there were murder and drug trafficking cases which attract the death penalty in the city-state. Often, the re-enactments of these capital cases would also show the final verdicts of the convicts, where it revealed the dates of their sentencing and/or executions. Notably, executed criminals like English serial killer John Martin Scripps, child killer Adrian Lim, notorious wife-killer Anthony Ler and cop-killer Zainal Abidin Abdul Malik featured in these re-enactment shows since the 1980s till the present.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.